AngioDynamics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended November 30, 2017. For the quarter, the company's net sales were $86,706,000 against $89,029,000 a year ago. Operating income was $1,123,000 against $15,588,000 a year ago. Income before income taxes was $83,000 against $14,415,000 a year ago. Net income was $249,000 against $13,734,000 a year ago. Earnings per basic and diluted share were $0.01 against $0.37 a year ago. Adjusted net income was $5,809,000 against $6,924,000 a year ago. Adjusted diluted earnings per share were $0.16 against $0.19 a year ago. EBITDA was $8,693,000 against $23,059,000 a year ago. Adjusted EBITDA was $13,335,000 against $15,171,000 a year ago. EBITDA per diluted share was $0.23 against $0.62 a year ago. Adjusted EBITDA was $0.36 against $0.41 a year ago. Net cash provided by operating activities was $10,165,000 against $14,947,000 a year ago. Additions to property, plant and equipment was $721,000 against $1,365,000 a year ago. Free cash flow of $9.4 million.

For the six months, the company's net sales were $172,117,000 against $177,127,000 a year ago. Operating income was $1,263,000 against $19,160,000 a year ago. Income before income taxes was $67,000 against $17,318,000 a year ago. Net income was $214,000 against $15,034,000 a year ago. Earnings per basic and diluted share were $0.01 against $0.41 a year ago. Adjusted net income was $10,401,000 against $13,322,000 a year ago. Adjusted diluted earnings per share were $0.28 against $0.36 a year ago. EBITDA was $16,990,000 against $34,518,000 a year ago. Adjusted EBITDA was $24,618,000 against $29,489,000 a year ago. EBITDA per diluted share was $0.46 against $0.93 a year ago. Adjusted EBITDA was $0.66 against $0.80 a year ago. Net cash provided by operating activities was $13,201,000 against $22,387,000 a year ago. Additions to property, plant and equipment was $1,222,000 against $1,846,000 a year ago.

For the year 2018, the company expects net sales in the range of $345 to $350 million, compared to the previous range of $352 to $359 million, and free cash flow in the range of $30 to $35 million down from greater than $35 million, excluding the potential cash payment related to the previously disclosed legal matters for the Department of Justice subpoenas. The company reaffirms its previously issued adjusted earnings per share guidance range of $0.64 to $0.68, excluding any impact from the recently enacted 2017 Tax Reform Act.